Clinical Trial: High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07834281) titled 'High-concentration Capsaicin Patch for the Prevention of Paclitaxel-induced Peripheral Neuropathy' on Sept. 17.

Brief Summary: This research study is for participants who are receiving paclitaxel infusion as part of their cancer treatment. The purpose of this study is to test the effectiveness of the Food and Drug Administration (FDA) approved high-concentration (8%) capsaicin patch (HCCP) in prevention of taxane-induced peripheral neuropathy (nerve pain in hands and/or feet). Participants will be randomized, like flipping a coin, into one of four groups. Group one will receive the HCCP on one hand and one foot 60 minutes prior to ...